NT5E — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Clofarabine (SCHEMBL9040)	0.69	8/20
SCHEMBL37272	0.51	8/20
SCHEMBL37437	0.51	8/20
Fludarabine Phosphate (SCHEMBL3511)	0.82	6/20
SCHEMBL218999	0.84	5/20
SCHEMBL156692	1.00	4/20
SCHEMBL196559	0.87	4/20
SCHEMBL154124	0.76	4/20
SCHEMBL151762	0.73	4/20
SCHEMBL156430	0.61	4/20
Water (SCHEMBL138858)	0.58	4/20
SCHEMBL152904	0.50	4/20
SCHEMBL258935	0.50	4/20
SCHEMBL122575	0.49	4/20
SCHEMBL242820	0.48	4/20
SCHEMBL152672	0.46	4/20
SCHEMBL158629	0.43	4/20
SCHEMBL150291	1.00	3/20
SCHEMBL121750	0.75	3/20
SCHEMBL66310	0.74	3/20

Clinical trials — most relevant to NT5E by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain	PHASE4	UNKNOWN
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Preventing Acute Kidney Injury (AKI) in Pediatric Patients	PHASE3	UNKNOWN
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)	PHASE1/PHASE2	RECRUITING
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2	PHASE2	NOT_YET_RECRUITING
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	PHASE2	RECRUITING
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer	PHASE2	UNKNOWN
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients	EARLY_PHASE1	RECRUITING
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Blood Sample Donations to Study the Role of Genes in Pain	nan	COMPLETED
Natural History Study for Patients With Nemaline Myopathy in Spain	nan	RECRUITING
Vasopressin and V2 Receptor in Meniere's Disease	nan	COMPLETED
Pathophysiology of Paget's Disease of Bone	nan	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Genetics of Neonatal Encephalopathy and Related Disorders	nan	RECRUITING
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
RAPA-501 Therapy of ALS Expanded Access Protocol	nan	TEMPORARILY_NOT_AVAILABLE
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3	nan	COMPLETED
Polymorphisms, Caffeine and Sleep Disorders	nan	COMPLETED
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD	nan	ENROLLING_BY_INVITATION
BATokines as Biomarkers of Brown Fat in Humans	nan	ACTIVE_NOT_RECRUITING
Genetic Epidemiology of Coronary Heart Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NT5E binder may also engage these)

Protein	Name	Similarity
Q05927	—	1.000	Q05927 →
P21588	—	0.992	P21588 →
Q61503	—	0.990	Q61503 →
F8S0Z7	—	0.988	F8S0Z7 →
B6EWW8	—	0.984	B6EWW8 →
W8EFS0	—	0.977	W8EFS0 →
A0A2I4HXH5	—	0.977	A0A2I4HXH5 →
P29240	—	0.956	P29240 →
Q9CZR2	—	0.953	Q9CZR2 →
O77564	—	0.952	O77564 →
Q3TIW9	—	0.950	Q3TIW9 →
NAALAD2	N-acetylated-alpha-linked acidic dipeptidase 2	0.950	landscape →
FOLH1	Glutamate carboxypeptidase 2	0.949	landscape →
ALPL	Alkaline phosphatase, tissue-nonspecific isozyme	0.949	landscape →
O35409	—	0.948	O35409 →
Q9HBA9	—	0.944	Q9HBA9 →
P09242	—	0.943	P09242 →
Q5RFI8	—	0.943	Q5RFI8 →
P58242	—	0.943	P58242 →
Q6UWV6	—	0.942	Q6UWV6 →
Q92485	—	0.942	Q92485 →
P70627	—	0.942	P70627 →
Q5RDN7	—	0.942	Q5RDN7 →
P08289	—	0.941	P08289 →
P15693	—	0.940	P15693 →
Q5EZ72	—	0.940	Q5EZ72 →
Q17QK3	—	0.939	Q17QK3 →
Q29486	—	0.939	Q29486 →
Q5RFG3	—	0.939	Q5RFG3 →
PGM2	Phosphopentomutase	0.937	landscape →